Sanofi: Press Releases, Tuesday, December 10, 2019
Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease Sutimlimab, a novel investigational C1s inhibitor, has the potential to be the first approved treatment for cold agglutinin disease, a serious, chronic, rare blood disorder Results met the primary and secondary endpoints and demonstrated rapid inhibition of hemolysis and clinically significant improvements in anemia...
READ MORE Sanofi: Press Releases, Tuesday, December 10, 2019